Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

Introducing our new Executive Officer – Dr. Rosalind Wilson (Ros)

Dr Rosalind Wilson has joined the ALTG team as our new full-time Executive Officer. Ros brings a mix of scientific and business skills to our group, as a graduate of Monash Medical School with an MBA from London Business School and a successful career in clinical development and commercialisation within the global pharmaceutical industry.

With Karen Lather’s move within Lung Foundation Australia, Dr Rosalind Wilson has joined the ALTG team as Executive Officer. Ros is a graduate of Monash Medical School and also holds an MBA from London Business School. After a brief stint in clinical practice Ros joined the pharmaceutical industry and worked for Roche in Australia, the UK and the company’s global headquarters in Switzerland over a 12 year period, starting in Medical Affairs and eventually leading the team that developed pertuzumab in HER2-overexpressing breast cancer. Ros has also consulted to Australian biotech companies, helping them to develop clinical research and product pipeline strategy. Ros is working fulltime with the ALTG, with the remit to help further develop and grow the group’s activities. She will also be supporting the group with its leadership role in establishing TACT. Ros is currently reviewing the ALTG’s strategy and activities, looking for opportunities to improve our effectiveness in developing and implementing new research concepts. She is keen to hear from our members so please feel free to send your feedback, ideas, comments and suggestions via email Rosalind@lungfoundation.com.au or phone (07) 3251 3628 (office) or 0481 394 982 (mobile).